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Incretin hormones such as glucagon-like peptide-1 (GLP-1) and
glucose-dependent insulinotropic polypeptide (GIP) facilitate gluco-
se-dependent insulin secretion from pancreatic β-cells (Baggio &
Drucker, 2017). It is known, however, that incretin effect is often
impaired in subjects with type 2 diabetes (Meier & Nauck, 2010).
Expression levels of incretin receptor are decreased under diabetic
conditions which are likely associated with the impaired incretin
effects (Xu et al., 2007). To compensate such impairment, incretin-
related medicine is often used for the treatment of type 2 diabetes.
Liraglutide is one of the GLP-1 analogues and is often used in practical
medicine. In this study, we examined which factors inﬂuence the
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2.1. Study subjects
Type 2 diabetic subjects who visited outpatient clinic of diabetes at
Kawasaki Medical School Hospital and newly started liraglutide were
eligible in this study. The hospital ethics committee approved the
study protocol, and informed consent was obtained from each patient
by showing it in our homepage after a full explanation of the study.2.2. Statistical analyses
Mann–Whitney U test was used to compare clinical characteristics
between effective and ineffective group. Wilcoxon signed-rank test
was used to compare values before and after treatment. All data were
analyzed using JMP version 11.0 and are shown as mean ± SE.3. Results
3.1. Study subjects
Baseline characteristics of the study subjects (n = 89) are as follows:
age, 59.2 ± 1.0 years old; BMI, 28.6 ± 0.5 kg/m2; duration of diabetes,
15.3 ± 0.8 years;HbA1c,8.1 ± 0.2%;glycoalbumin,21.4 ± 0.4%;C-peptide
immunoreactivity (CPR) index (fasting CPR to glucose ratio), 2.0 ± 0.2;
systolic blood pressure, 131 ± 1 mmHg; diastolic blood pressure, 73 ±nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1202 A. Tanabe et al. / Journal of Diabetes and Its Complications 30 (2016) 1201–12031 mmHg; fasting triglycerides, 131 ± 8 mg/dl; LDL cholesterol, 101 ±
3 mg/dl; HDL cholesterol, 49 ± 1 mg/dl.
3.2. Effects of liraglutide on glycemic control and body mass index
HbA1c levels were signiﬁcantly decreased after the treatment with
liraglutide (baseline HbA1c, 8.11 ± 0.21%; 1 month, 7.58 ± 0.10%;
3 month, 7.39 ± 0.10%; 6 month, 7.40 ± 0.10%; 9 month, 7.40 ±
0.10%; 12 month, 7.52 ± 0.14%) (p b 0.01 for each point vs baseline).
BMI was also signiﬁcantly decreased after the treatment (baseline
BMI, 28.9 ± 0.15; 1 month, 28.3 ± 0.10; 3 month, 28.2 ± 0.10;
6 month, 28.0 ± 0.10; 9 month, 28.1 ± 0.10; 12 month 28.1 ±
0.10) (p b 0.01 for each point vs baseline).
3.3. Comparison of clinical background between effective and
ineffective group
Liraglutide was effective for some subjects (n = 49) but not for
other subjects (n = 40) 12 months after starting liraglutide. Effec-
tiveness was deﬁned as follows: decrease of HbA1c level from baseline
HbA1c ≥0.5%. HbA1c level at every point after starting liraglutide in
effective group was signiﬁcantly decreased (baseline HbA1c, 8.38 ±
0.13%; 1 month, 7.67 ± 0.12%; 3 month, 7.26 ± 0.13%; 6 month,
7.19 ± 0.12%; 9 month, 7.14 ± 0.12%; 12 month, 7.11 ± 0.12%)
(p b 0.05 for each point vs baseline). HbA1c level in ineffective
group were as follows: baseline HbA1c, 7.75 ± 0.14%; 1 month,
7.47 ± 0.16%; 3 month, 7.56 ± 0.16%; 6 month, 7.65 ± 0.16%;
9 month, 7.66 ± 0.16%; 12 month, 8.03 ± 0.16%. The value of
HbA1c in effective group was signiﬁcantly lower than that in
ineffective group 6, 9 and 12 months after starting the treatment
(p b 0.05).
To elucidate which factors are related with the efﬁcacy of
liraglutide, we compared the clinical background between effective
and ineffective group. Baseline HbA1c level was signiﬁcantly higher in
the effective group compared to ineffective group (8.4 ± 0.1 vs 7.8 ±
0.1%) (p b 0.05) (Table 1). CPR index was also higher in the effective
group compared to ineffective group (2.1 ± 0.2 vs 1.4 ± 0.3)
(p b 0.05) (Table 1). These results suggest that liraglutide is more
useful in subjects preserving β-cell function. There was no signiﬁcant
difference in other factors between effective and ineffective group
(age, 61.0 ± 1.7 vs 59.8 ± 1.5 years old; BMI, 29.8 ± 1.0 vs 28.0 ±
0.7 kg/m2; duration of diabetes, 14.6 ± 1.3 vs 15.0 ± 1.2 years;
systolic blood pressure, 133.1 ± 2.4 vs 128.3 ± 1.9 mmHg; diastolic
blood pressure, 72.6 ± 1.4 vs 73.9 ± 1.7 mmHg; fasting triglycerides,
120.3 ± 8.9 vs 137.8 ± 12.7 mg/dl; LDL cholesterol, 102.3 ± 4.8 vs
102.0 ± 5.0 mg/dl; HDL cholesterol, 49.0 ± 2.8 vs 48.2 ± 1.5 mg/dl).Table 1
Association of ΔHbA1c (from baseline to 3 month) with various clinical parameters.
Univariate analysis Multivariate analysis
Clinical parameter ρ p t p
Age −0.52 n.s.
Gender −0.36 n.s.
Baseline BMI −0.07 n.s.
Baseline HbA1c −0.49 b0.01 −2.94 b0.01
Duration of diabetes 0.17 n.s. 1.45 n.s.
CPR index −0.12 n.s. 0.53 n.s.
Systolic blood pressure −0.23 b0.05 −0.36 n.s.
Diastolic blood pressure −0.03 n.s.
Fasting triglycerides 0.29 b0.05 2.34 b0.05
LDL cholesterol 0.04 n.s. 0.26 n.s.
HDL cholesterol 0.13 n.s. −0.12 n.s.
Dose of insulin 1.13 n.s.
Abbreviations: BMI, body mass index; CPR, C-peptide immunoreactivity; LDL,
Low-density lipoprotein; HDL, high-density lipoprotein; n.s. not signiﬁcant. Data are
described as mean ± SE.3.4. Determinant factors for the efﬁcacy of liraglutide on HbA1c levels
To examine which factors are associated with the amelioration of
HbA1c from baseline to 3 month after the treatment, we performed
univariate analyses. As shown in Table 1, baseline HbA1c, systolic
blood pressure and fasting triglyceride levels were closely associated
with ΔHbA1c (0–3 month) in these subjects (p b 0.05).
Next, to elucidate which are independent factors determining the
efﬁcacy of liraglutide after the adjustment with age and gender, we
performed multivariate regression analyses including age, gender,
baseline HbA1c, duration of diabetes, CPR index, systolic blood pressure,
fasting triglycerides, LDL cholesterol, HDL cholesterol and dose of insulin
as independent variables. As shown in Table 1, fasting triglyceride level as
well as baselineHbA1c levelwere independent factors contributing to the
efﬁcacy of liraglutide. These results suggest that triglyceridemanagement
is important for the efﬁcacy of liraglutide.
3.5. Determinant factors for the durability of liraglutide on HbA1c levels
To examine which factors are associated with the amelioration of
HbA1c levels from 3 to 12 month after the treatment, we performed
univariate analyses. As shown in Table 2, CPR index was closely
associated with ΔHbA1c (3–12 month).
Next, to elucidate the independent factors determining the efﬁcacy
of liraglutide after the adjustment with age and gender, we performed
multivariate analyses including age, gender, baseline HbA1c, duration
of diabetes, CPR index, and fasting triglycerides. As shown in Table 2,
CPR index was an independent factor contributing to the durability of
liraglutide. These results suggest that remaining β-cell function is
important for the durability of liraglutide.
4. Discussion
It has been reported that prolonged exposure to free fatty acids
reduces β-cell function and that amelioration of lipid control
preserves β-cell function (Giacca, Xiao, Oprescu, Carpentier, &
Lewis, 2010). We think that the data in this study are compatible
with such reports. It was also reported that elevated free fatty acids
impaired responsiveness to GLP-1 through the down-regulation of
GLP-1 receptor signaling (Hodson et al., 2013; Kang et al., 2013).
Therefore, although speculative, we assume that inadequate triglyc-
eride management reduces GLP-1 receptor expression which possibly
reduces the efﬁcacy of liraglutide. It is noted, however, that this is our
hypothesis and that it remains unknown whether CPR and/or
impaired β-cell function directly leads to the reduction of liraglutide
efﬁcacy. In addition, since it is known that there is a cross-talk
between insulin signaling and GLP-1 signaling in β-cells, we think thatTable 2
Association of ΔHbA1c (from 3 month to 12 month) with various clinical parameters.
Univariate analysis Multivariate analysis
Clinical parameter ρ p t p
Age −0.70 n.s.
Gender −1.98 n.s.
Baseline BMI −0.05 n.s.
Baseline HbA1c −0.09 n.s. −0.88 n.s.
Duration of diabetes 0.15 n.s. −0.05 n.s.
CPR index −0.46 b0.01 −2.51 b0.05
Systolic blood pressure 0.11 n.s.
Diastolic blood pressure −0.04 n.s.
Fasting triglycerides −0.32 n.s. 0.53 n.s.
LDL cholesterol −0.11 n.s.
HDL cholesterol 0.22 n.s.
Abbreviations: BMI, body mass index; CPR, C-peptide immunoreactivity; LDL,
Low-density lipoprotein; HDL, high-density lipoprotein; n.s. not signiﬁcant. Data are
described as mean ± SE.
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It has been also reported that chronic exposure to excess triglyceride
impairs GLP-1R signaling whereas acute exposure to triglyceride
increases GLP-1R expression in human β-cells (Hodson et al., 2013).
Therefore, we should keep in mind that there is a large difference
between the effects of chronic and acute exposure to triglyceride.
All subjects in this study were Japanese, and thus we think that
there was no big difference in ethnicity. However, some type 2
diabetes risk alleles such as TCF7L2 are known to be associated with
response to incretin (Villareal et al., 2010). Since we did not evaluate
type 2 diabetes risk alleles in this study, we cannot exclude the
possibility that some difference in type 2 diabetes risk alleles
inﬂuenced the results in this study. In addition, although triglyceride
concentration was identiﬁed by multivariate analysis as being
associated with liraglutide efﬁcacy, there was no statistically
signiﬁcant difference in triglyceride levels between liraglutide
responders and non-responders. Although mean value of triglyceride
in responders (120.3 ± 8.9 mg/dl) was lower compared to that in
non-responders (137.8 ± 12.7 mg/dl), we think that number of study
subjects was not large enough to reach statistical signiﬁcance and that
further study with larger number of subjects would be important.
In conclusion, clinical effects of liraglutide are possibly inﬂuenced
by hypertriglyceridemia and remaining β-cell function in subjects
with type 2 diabetes. Therefore, it would be better to pay attention totriglyceride management and remaining β-cell function when we use
liraglutide in subjects with type 2 diabetes. However, to strengthen
our conclusion, it would be important to perform some interventional
studies such as the evaluation of liraglutide efﬁcacy after lowering
triglyceride levels in subjects with type 2 diabetes.
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